Waycross Partners’s Eli Lilly LLY Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
Sell
-4,000
Closed -$4.3M 93
2025
Q4
$4.3M Hold
4,000
0.35% 32
2025
Q3
$3.05M Hold
4,000
0.26% 45
2025
Q2
$3.12M Hold
4,000
0.29% 38
2025
Q1
$3.3M Hold
4,000
0.37% 35
2024
Q4
$3.09M Sell
4,000
-1,000
-20% -$828K 0.4% 34
2024
Q3
$4.43M Hold
5,000
0.61% 31
2024
Q2
$4.53M Sell
5,000
-1,000
-17% -$800K 0.69% 31
2024
Q1
$4.67M Sell
6,000
-500
-8% -$356K 0.8% 31
2023
Q4
$3.79M Sell
6,500
-2,400
-27% -$1.4M 0.71% 33
2023
Q3
$4.78M Sell
8,900
-2,950
-25% -$1.52M 1.06% 29
2023
Q2
$5.56M Sell
11,850
-23,806
-67% -$9.98M 1.21% 28
2023
Q1
$12.2M Buy
35,656
+5,121
+17% +$1.73M 3.56% 6
2022
Q4
$11.2M Buy
30,535
+12,425
+69% +$4.41M 4.05% 4
2022
Q3
$5.86M Buy
18,110
+4,095
+29% +$1.3M 3.94% 3
2022
Q2
$4.54M Sell
14,015
-3,532
-20% -$1.06M 3.02% 6
2022
Q1
$5.03M Buy
17,547
+708
+4% +$182K 2.93% 7
2021
Q4
$4.65M Buy
16,839
+2,739
+19% +$694K 2.66% 6
2021
Q3
$3.26M Sell
14,100
-3,387
-19% -$836K 2.05% 13
2021
Q2
$4.01M Buy
17,487
+1,874
+12% +$376K 2.13% 17
2021
Q1
$2.92M Buy
+15,613
New +$3.05M 1.63% 23

Other funds holding LLY

Waycross Partners's LLY Position: Q1 2026 in Review

Waycross Partners sold out of Eli Lilly (LLY) in Q1 2026, closing a stake of 4,000 shares — an estimated $4.3M sold.

Waycross Partners first reported a position in LLY in Q1 2021 and held it in 20 quarters. The position peaked at $12.2M in Q1 2023. 4,379 funds tracked by Wall St. Rank hold LLY as of Q1 2026.

  • Waycross Partners reported no remaining Eli Lilly position as of Q1 2026 after selling out during the quarter.
  • Waycross Partners sold 4,000 Eli Lilly shares in Q1 2026, an estimated $4.3M.
  • Waycross Partners first reported a position in Eli Lilly in Q1 2021 and held it in 20 quarters.
  • Waycross Partners's Eli Lilly position peaked at $12.2M in Q1 2023.
  • 4,379 funds tracked by Wall St. Rank held Eli Lilly as of Q1 2026.

Based on Waycross Partners's 13F filing for Q1 2026, filed 7 May 2026.